AOA presses for FDA enforcement focused on ‘Eyebot’ Kiosk

Published on March 25, 2026
Detailed legal complaint documents patient safety, health and product claim concerns—and seeks immediate federal agency enforcement action.
Continue reading on website
Other news

LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum

March 25, 2026
SAN DIEGO—LENZ Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, yesterday reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update. Approved by the FDA in July 2025, VIZZ is a once-daily aceclidine-based eye drop for the treatment of age-related

Beware of Sensationalizing the Potential Semaglutide-NAION Link

March 26, 2026
Few articles analyzed in this study situated NAION within its known risk factors, including its associations with age, diabetes, hypertension and obstructive sleep apnea. Without this information, the semaglutide-NAION link may seem more novel or direct than warranted. Misinformation can arise not just from factual inaccuracies but also from exclusion of context or distortion of framing. Photo: Mi